Barnett James D, Jin Jiefu, Penet Marie-France, Kobayashi Hisataka, Bhujwalla Zaver M
Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Cancers (Basel). 2022 Jul 22;14(15):3578. doi: 10.3390/cancers14153578.
(1) Background: MDSCs play an active role in the immune surveillance escape of cancer cells. Because MDSCs in mice are CD11bGr1, near-infrared photoimmunotherapy (NIR-PIT) using the NIR dye IR700 conjugated to an MDSC-binding antibody provides an opportunity for targeted elimination of MDSCs. (2) Methods: The efficacy of Gr1-IR700-mediated NIR-PIT was evaluated in vitro using magnetically separated CD11bGr1 MDSCs from spleens of 4T1-luc tumor-bearing (TB) mice. For in vivo evaluation, spleens of Gr1-IR700-injected 4T1-luc TB mice were irradiated with NIR light, and splenocyte viability was determined using CCK-8 assays. Metabolic profiling of NIR-PIT-irradiated spleens was performed using H MRS. (3) Results: Flow cytometric analysis confirmed a ten-fold increase in splenic MDSCs in 4T1-luc TB mice. Gr1-IR700-mediated NIR-PIT eliminated tumor-induced splenic MDSCs in culture. Ex vivo fluorescence imaging revealed an 8- and 9-fold increase in mean fluorescence intensity (MFI) in the spleen and lungs of Gr1-IR700-injected compared to IgG-IR700-injected TB mice. Splenocytes from Gr1-IR700-injected TB mice exposed in vivo to NIR-PIT demonstrated significantly lower viability compared to no light exposure or untreated control groups. Significant metabolic changes were observed in spleens following NIR-PIT. (4) Conclusions: Our data confirm the ability of NIR-PIT to eliminate splenic MDSCs, identifying its potential to eliminate MDSCs in tumors to reduce immune suppression. The metabolic changes observed may identify potential biomarkers of splenic MDSC depletion as well as potential metabolic targets of MDSCs.
(1) 背景:髓系来源的抑制性细胞(MDSCs)在癌细胞的免疫监视逃逸中发挥着积极作用。由于小鼠中的MDSCs是CD11bGr1,使用与MDSC结合抗体偶联的近红外染料IR700进行近红外光免疫疗法(NIR - PIT)为靶向清除MDSCs提供了机会。(2) 方法:使用从4T1 - luc荷瘤(TB)小鼠脾脏中磁分离出的CD11bGr1 MDSCs在体外评估Gr1 - IR700介导的NIR - PIT的疗效。对于体内评估,用近红外光照射注射了Gr1 - IR700的4T1 - luc TB小鼠的脾脏,并使用CCK - 8测定法确定脾细胞活力。使用氢磁共振波谱(H MRS)对接受NIR - PIT照射的脾脏进行代谢谱分析。(3) 结果:流式细胞术分析证实4T1 - luc TB小鼠脾脏中的MDSCs增加了10倍。Gr1 - IR700介导的NIR - PIT在培养物中消除了肿瘤诱导的脾脏MDSCs。离体荧光成像显示,与注射IgG - IR700的TB小鼠相比,注射Gr1 - IR700的TB小鼠的脾脏和肺中的平均荧光强度(MFI)分别增加了8倍和9倍。在体内接受NIR - PIT照射的注射Gr1 - IR700的TB小鼠的脾细胞与未照射或未处理的对照组相比,活力显著降低。在NIR - PIT后脾脏中观察到显著的代谢变化。(4) 结论:我们的数据证实了NIR - PIT清除脾脏MDSCs的能力,确定了其消除肿瘤中MDSCs以减少免疫抑制的潜力。观察到的代谢变化可能确定脾脏MDSC耗竭的潜在生物标志物以及MDSCs的潜在代谢靶点。